Revenue was nearly quadruple the level in the same quarter last year
Featured articles
US regulators have given the green light for the opioid Dsuvia to be used under strict medical...
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the...
The treatment Zynberba is developing is for Fragile X Syndrome, the leading known genetic cause...
Its Phase 3 clinical trial of eye disease drug Xipere failed to meet its primary endpoint
New data will be unveiled later Monday at a cancer conference in Glasgow
Featured companies
Sphere Medical is a dynamic company specialising in the development of innovative medical moni...
Sativa seeks to invest in companies which are well-placed to take advantage of the dynamic reg...
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural m...
Orgenesis is a development stage company with a novel therapeutic approach in the treatment of...
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietar...
Phzio started as an idea to enable Physical Therapists with better access to their patients. W...
Global biotech Newswire
Revenue was nearly quadruple the level in the same quarter last year
AcelRx shares pop on FDA approval of opioid pain treatment Dsuvia
November 05 2018
US regulators have given the green light for the opioid Dsuvia to be used under strict medical...
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the...
The treatment Zynberba is developing is for Fragile X Syndrome, the leading known genetic cause...
Dr Lang is an internationally renowned cardiologist and specialist in echocardiography..
Aequus Pharmaceuticals establishes advisory board in ophthalmology
November 05 2018
They are Dr Ike Ahmed who will become chairman and Dr Rosa Braga-Mele, who comes from the...
Its Phase 3 clinical trial of eye disease drug Xipere failed to meet its primary endpoint
N4 Pharma surges as MedImmune agrees to extend collaboration deal
November 05 2018
The two parties had been working together as part of a project funded by the UK government and...
Having complete ownership of the US subsidiary is particularly important, said Angle, as it owns...
Executive video interviews
In part two of two announcements concerning Orgenesis (NASDAQ: ORGS) and HemoGenyx...
In part one of two announcements concerning Orgenesis (NASDAQ: ORGS) and HemoGenyx...
Collagen Solutions PLC (LON:COS) CEO Jamal Rushdy and CFO Hilary Spence speak to...
Manx Telecom (LON:MANX) chief executive Gary Lamb speaks to Proactive Investors about...
Dr Markku Jalkanen, CEO of Faron Pharmaceuticals Oy (LON:FARN), tells Proactive London's...
Biotech Actinogen has signed 174 patients for its trial of the drug Xanamem, which may...
Medlab Clinical (ASX:MDC) has completed the first stage medical trials of its NanaBis...
Small cap names on the move today are: Pyxus (NYSE:PYX), Acorda Therapeutics...
Arix Bioscience Plc (LON:ARIX) portoflio company Iterum Therapeutics Plc (NASDAQ:ITRM)...
Orgenesis Inc (NASDAQ:ORGS) CEO Vered Caplan and General Manager Ohad Karnieli tells...
Futura Medical PLC's (LON:FUM) finance director and chief operating officer Angela...
Iterum Therapeutics Plc (NASDAQ:ITRM) CEO Corey Fishman tells Proactive's Christine...
Big picture investment ideas in Biotech Capital
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been...
The company sells clinically validated anti-ageing products for hair, skin and body.
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for...
The company, which owns a piece of software which predicts the effects of drugs on cancers, has...
The cancer detection device is on track to finish a key clinical study in the first quarter of...
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release...
The Californian company is a bet on an industry that is in need of transformation
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve...
Summit has big plans for its flagship ridinilazole C. Diff treatment as well as its gonorrhoea...
Capital Network Research
Avacta Group - Maximising Affimer's potential across therapeutics and...
October 03 2018
Over the last year or so, management has delivered significant progress in bringing their...
Judges Scientific PLC - 2018 Interim Results
September 21 2018
Judges Scientific reported results for the first half of 2018. The period included a...
Legendary Investments - Hidden value potential
September 03 2018
Legendary Investments (LON:LEG) creates value through privately held and pre-market...
Avacta Group - Exciting partnership with Bach BioSciences
July 30 2018
Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with...
Avacta Group - Rapid Progress of Immuno-oncology Programs
April 16 2018
KEY INVESTOR MESSAGES
Faster than expected development of the second immuno-oncology...
Summit Therapeutics Plc - Stock Valuation Undemanding
April 03 2018
- Key inflection point: topline data readout from the PhaseOut DMD phase 2 trial in Duchenne...
Partners:
